DK0759032T3 - Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf - Google Patents

Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf

Info

Publication number
DK0759032T3
DK0759032T3 DK95914752T DK95914752T DK0759032T3 DK 0759032 T3 DK0759032 T3 DK 0759032T3 DK 95914752 T DK95914752 T DK 95914752T DK 95914752 T DK95914752 T DK 95914752T DK 0759032 T3 DK0759032 T3 DK 0759032T3
Authority
DK
Denmark
Prior art keywords
mage
hla
complexing
molecules
peptides derived
Prior art date
Application number
DK95914752T
Other languages
English (en)
Inventor
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Katharina Fleischauer
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK0759032T3 publication Critical patent/DK0759032T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/828Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95914752T 1994-03-24 1995-03-21 Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf DK0759032T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,187 US5554506A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003408 WO1995025739A1 (en) 1994-03-24 1995-03-21 Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof

Publications (1)

Publication Number Publication Date
DK0759032T3 true DK0759032T3 (da) 1999-12-27

Family

ID=22810011

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95914752T DK0759032T3 (da) 1994-03-24 1995-03-21 Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf

Country Status (16)

Country Link
US (3) US5554506A (da)
EP (1) EP0759032B1 (da)
JP (1) JP3451356B2 (da)
CN (1) CN1142177C (da)
AT (1) ATE183195T1 (da)
AU (1) AU682956B2 (da)
CA (1) CA2186005A1 (da)
DE (1) DE69511399T2 (da)
DK (1) DK0759032T3 (da)
ES (1) ES2135051T3 (da)
FI (1) FI963781A7 (da)
GR (1) GR3031811T3 (da)
NZ (1) NZ283543A (da)
TW (1) TW496875B (da)
WO (1) WO1995025739A1 (da)
ZA (1) ZA952376B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6087441A (en) 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
ATE377022T1 (de) 1997-06-23 2007-11-15 Ludwig Inst Cancer Res Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
WO2001053833A1 (en) * 2000-01-20 2001-07-26 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
ES2373055T3 (es) * 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
FI963781L (fi) 1996-09-23
EP0759032A1 (en) 1997-02-26
WO1995025739A1 (en) 1995-09-28
ATE183195T1 (de) 1999-08-15
CN1151167A (zh) 1997-06-04
JPH10500667A (ja) 1998-01-20
US5554506A (en) 1996-09-10
FI963781A0 (fi) 1996-09-23
EP0759032B1 (en) 1999-08-11
EP0759032A4 (en) 1997-04-09
ZA952376B (en) 1995-12-14
CA2186005A1 (en) 1995-09-28
AU682956B2 (en) 1997-10-23
ES2135051T3 (es) 1999-10-16
JP3451356B2 (ja) 2003-09-29
TW496875B (en) 2002-08-01
DE69511399T2 (de) 2000-05-11
US6353089B1 (en) 2002-03-05
FI963781A7 (fi) 1996-09-23
DE69511399D1 (de) 1999-09-16
NZ283543A (en) 1998-04-27
GR3031811T3 (en) 2000-02-29
AU2187095A (en) 1995-10-09
US6019987A (en) 2000-02-01
CN1142177C (zh) 2004-03-17

Similar Documents

Publication Publication Date Title
DK0759032T3 (da) Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
ES2080717T3 (es) Hibridomas productores de anticuerpos monoclonales para nuevos epitopos de mucina.
DE60039448D1 (de) Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
HUT38300A (en) Process for producing growth-controlling composition attached to the platelets
EP0711173A4 (en) INSULATED PEPTIDES THAT MAKE 10 COMPLEXES WITH MHC MULEKÜL HLA-C-KLON AND THEIR USE
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
NO963917L (no) Isolerte, MAGE-3-avledete peptider som komplekserer med HLA-A2-molekyler, samt anvendelser derav
RU2000132677A (ru) Моноклональное антитело ико25, специфичное к антигену мис1, противоопухолевое средство